Rating to Follow: Coherus BioSciences (NASDAQ:CHRS) Is Now Covered By Standpoint Research. What to Expect?

November 25, 2016 - By whatsonthorold

Rating to Follow: Coherus BioSciences (NASDAQ:CHRS) Is Now Covered By Standpoint Research. What to Expect?

Why Standpoint Research Gives Coherus BioSciences (NASDAQ:CHRS) $40.00 Price Target

In a analysts note released on Friday morning, expert analysts at Standpoint Research started coverage on shares of Coherus BioSciences (NASDAQ:CHRS). The firm set a Speculative Buy rating with $40.00, giving 42.86% to target.

Coherus Biosciences Inc (NASDAQ:CHRS) Ratings Coverage

Out of 6 analysts covering Coherus Biosciences (NASDAQ:CHRS), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. $46 is the highest target while $36 is the lowest. The $41.25 average target is 47.32% above today’s ($28) stock price. Coherus Biosciences has been the topic of 6 analyst reports since September 3, 2015 according to StockzIntelligence Inc. Barclays Capital initiated the stock with “Overweight” rating in Monday, November 23 report. The firm has “Buy” rating given on Wednesday, September 7 by Maxim Group. Robert W. Baird initiated it with “Outperform” rating and $40 target price in Wednesday, October 19 report. The rating was initiated by Credit Suisse with “Outperform” on Wednesday, January 20. Citigroup initiated the stock with “Buy” rating in Wednesday, July 27 report. The firm has “Hold” rating by Zacks given on Thursday, September 3.

The stock decreased 0.36% or $0.1 during the last trading session, hitting $28. About 194,935 shares traded hands. Coherus Biosciences Inc (NASDAQ:CHRS) has risen 29.25% since April 22, 2016 and is uptrending. It has outperformed by 23.85% the S&P500.

Analysts await Coherus Biosciences Inc (NASDAQ:CHRS) to report earnings on March, 6. They expect $-1.63 EPS, down 20.74% or $0.28 from last year’s $-1.35 per share. After $1.67 actual EPS reported by Coherus Biosciences Inc for the previous quarter, Wall Street now forecasts -197.60% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 2.52 in Q2 2016. Its down 0.80, from 3.32 in 2016Q1. The ratio fall, as 10 funds sold all Coherus Biosciences Inc shares owned while 9 reduced positions. 22 funds bought stakes while 41 increased positions. They now own 49.39 million shares or 180.37% more from 17.62 million shares in 2016Q1.

Brown Advisory last reported 0.02% of its portfolio in the stock. Proshare Advsrs Ltd Liability accumulated 0.01% or 32,741 shares. Bourgeon Capital Mgmt Limited Liability Corp has invested 0.15% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Lord Abbett And Ltd Limited Liability Company reported 268,573 shares or 0.01% of all its holdings. Schwab Charles Invest Mngmt Incorporated has invested 0% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Moreover, Cormorant Asset Mgmt Limited Company has 1.38% invested in Coherus Biosciences Inc (NASDAQ:CHRS) for 576,106 shares. Royal Bancorp Of Canada accumulated 0% or 600 shares. New York State Common Retirement Fund accumulated 30,200 shares or 0% of the stock. Moreover, Columbus Circle has 0.06% invested in Coherus Biosciences Inc (NASDAQ:CHRS) for 373,249 shares. California State Teachers Retirement accumulated 0% or 61,840 shares. Axa owns 407,592 shares or 0.03% of their US portfolio. Rock Springs Capital Management L P has invested 0.5% of its portfolio in Coherus Biosciences Inc (NASDAQ:CHRS). Nationwide Fund Advsrs last reported 0% of its portfolio in the stock. Moreover, Vanguard has 0% invested in Coherus Biosciences Inc (NASDAQ:CHRS) for 1.01M shares. Voya Management Ltd Limited Liability Company last reported 0% of its portfolio in the stock.

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The company has a market cap of $1.24 billion. The Firm is focused on the global biosimilar market. It currently has negative earnings. The Firm operates through developing and commercializing biosimilar products segment.

According to Zacks Investment Research, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.”

CHRS Company Profile

Coherus BioSciences, Inc., incorporated on September 29, 2010, is a late-stage clinical biologics platform company. The Firm is focused on the global biosimilar market. The Firm operates through developing and commercializing biosimilar products segment. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

More recent Coherus Biosciences Inc (NASDAQ:CHRS) news were published by: Fool.com which released: “Why Coherus BioSciences, Inc. Is Dropping Today” on November 07, 2016. Also Fool.com published the news titled: “Why Coherus BioSciences Plunged 37% in January” on February 12, 2016. Globenewswire.com‘s news article titled: “Coherus BioSciences Appoints Patrick O’Brien as Senior Vice President …” with publication date: May 16, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>